IJU case reports · 2026
Apalutamide-Induced Hypothyroidism Associated With Increased Thyroid Hormone Clearance in Metastatic Prostate Cancer Patient: A Case Report.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Furumido Jun, Yamashita Akihiro, Kato Ryo, Hori Kanta
Аннотация
INTRODUCTION: Apalutamide (APA) is an androgen receptor signaling inhibitor widely used for metastatic hormone-sensitive prostate cancer (mHSPC), though it can induce hypothyroidism. We report a severe case of APA-induced hypothyroidism in a patient with a history of total thyroidectomy.
CASE PRESENTATION: A 65-year-old man receiving levothyroxine (175 μg/day) after thyroidectomy was diagnosed with mHSPC (Gleason score 4 + 4; PSA 13 904 ng/mL) with findings suggestive of cancer-associated disseminated intravascular coagulation. Following APA initiation (240 mg/day), PSA decreased rapidly to 0.01 ng/mL. However, TSH levels rose progressively despite increasing levothyroxine to 275 μg/day. After a 4-month follow-up interruption, TSH reached 187.9 mIU/L. APA withdrawal led to rapid TSH improvement.
CONCLUSION: Careful TSH monitoring is essential during APA treatment, especially in patients with pre-existing thyroid dysfunction or prior thyroidectomy. Appropriate levothyroxine titration and multidisciplinary collaboration are essential for the continuation of oncological therapy with APA.
CASE PRESENTATION: A 65-year-old man receiving levothyroxine (175 μg/day) after thyroidectomy was diagnosed with mHSPC (Gleason score 4 + 4; PSA 13 904 ng/mL) with findings suggestive of cancer-associated disseminated intravascular coagulation. Following APA initiation (240 mg/day), PSA decreased rapidly to 0.01 ng/mL. However, TSH levels rose progressively despite increasing levothyroxine to 275 μg/day. After a 4-month follow-up interruption, TSH reached 187.9 mIU/L. APA withdrawal led to rapid TSH improvement.
CONCLUSION: Careful TSH monitoring is essential during APA treatment, especially in patients with pre-existing thyroid dysfunction or prior thyroidectomy. Appropriate levothyroxine titration and multidisciplinary collaboration are essential for the continuation of oncological therapy with APA.